Athersys, Inc. Sustainability Profile
Athersys, Inc., a pioneering biotechnology company headquartered in the United States, focuses on developing innovative therapies for critical medical conditions. Founded in 1998, Athersys has made significant strides in the field of regenerative medicine, particularly through its proprietary MultiStem® cell therapy platform. This unique technology harnesses the power of stem cells to address various diseases, including neurological disorders and cardiovascular conditions. With a strong presence in the US and collaborations across Europe and Asia, Athersys is well-positioned in the competitive biotech landscape. The company has achieved notable milestones, including successful clinical trials and partnerships that enhance its market reach. Athersys continues to advance its mission of transforming patient care through cutting-edge science and a commitment to improving health outcomes.
DitchCarbon Score
How does Athersys, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Athersys, Inc.'s score of 17 is lower than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Athersys, Inc.'s reported carbon emissions
Athersys, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time. As there are no emissions data or reduction initiatives available, Athersys, Inc. appears to be in the early stages of developing a comprehensive climate strategy. In the context of the biotechnology industry, it is increasingly important for companies to adopt measurable climate commitments and reduction targets to align with global sustainability goals.
How Carbon Intensive is Athersys, Inc.'s Industry?
How Carbon Intensive is Athersys, Inc.'s Location?
Athersys, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Athersys, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
